Zoetis Inc. ZTS
71.05
0.78
1.11%
as of 25 Sep
- Market cap
- $29.2B
- P/E
- 11.7×
Follow ZTS
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Zoetis Inc. (ZTS) Return on assets
Zoetis Inc.'s return on assets over the twelve months to 30 June 2026 was 17.8%, down 0.2 percentage points from fiscal 2025 (18.0%). Over the past ten years it has ranged from 4.68% (fiscal 2015) to 18.0% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers Specialty & Generic industry median of −3.32% and above the Healthcare sector median of −30.9%.
Return on assets, annual
Annual
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | 18.0% | 0.57 |
| FY2024 | 17.4% | 1.38 |
| FY2023 | 16.1% | 1.38 |
| FY2022 | 14.7% | (0.14) |
| FY2021 | 14.8% | 1.79 |
| FY2020 | 13.0% | (0.42) |
| FY2019 | 13.4% | (1.31) |
| FY2018 | 14.8% | 4.11 |
| FY2017 | 10.6% | 0.09 |
| FY2016 | 10.6% | 5.87 |
Against its own ten years
Low 4.68%
High 18.0%
Ten-year median
14.7%
Current reading's percentile
100
Return on assets against peers
| Company | Return on assets |
|---|---|
| ZTS Zoetis Inc. | 17.8% |
| UTHR United Therapeutics Corporation compare | 17.3% |
| NBIX Neurocrine Biosciences, Inc. compare | 15.3% |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.55% |
| TAK Takeda Pharmaceutical Co. compare | 2.15% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 1.77% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. compare | −1.12% |
| ELAN Elanco Animal Health Incorporated compare | −1.46% |
| Drug Manufacturers Specialty & Generic industry median | −3.32% |
| Healthcare sector median | −30.9% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ZTS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement